Darbepoetin alfa: Potential role in managing anemia in cancer patients

Expert Review of Anticancer Therapy

Volumn 2, Issue 4, 2002, Pages 377-384

  Pirker, Robert ^a   Smith, Robert ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Anemia; Cancer; Chemotherapy; Darbepoetin alfa; Epoetin; Hemoglobin; Novel erythropoiesis; Quality of life; Radiotherapy; Stimulating protein

Indexed keywords

NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; PLATINUM; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER PATIENT; CHEMOTHERAPY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; EUROPEAN UNION; FATIGUE; FOOD AND DRUG ADMINISTRATION; HUMAN; NAUSEA AND VOMITING; PRACTICE GUIDELINE; QUALITY OF LIFE; TREATMENT OUTCOME; UNITED STATES; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; METABOLISM; NEOPLASM; REVIEW;

ANEMIA; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; ERYTHROPOIETIN; HUMANS; NEOPLASMS; QUALITY OF LIFE;

EID: 0036685204     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.2.4.377     Document Type: Article

References (43)

1. Anaemia in cancer pathophysiology and treatment
2. Chemotherapy-induced anemia in adults: Incidence and treatment
3. Radiotherapy-associated anemia: The scope of the problem
4. Symptomatology of anemia
5. Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors
6. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix
7. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study
8. Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review
9. Effects of epoetin-α on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy, results of a randomized, double-blind placebo-controlled trial
10. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx
11. Anemia is associated with high cost in newly diagnosed cancer patients
12. Anaemia and its functional consequences in cancer patients: Current challenges in management and prospects for improving therapy
13. Epoetin-β (NeoRecormon) package insert
14. Quality-of-life benefit in chemotherapy patients treated with epoetin-α is independent of disease response or tumor type: Results from a prospective community oncology study
15. Epoetina-α therapy increases hemoglobin levels and improves quality of life in patients with cancer-related anemia who are not receiving chemotherapy and patients with anemia who are receiving chemotherapy
16. Clinical evaluation of once-weekly dosing of epoetin-α in chemotherapy patients: Improvements in hemoglobin and quality of life are similar to three-times weekly dosing
17. Erythropoietin for anaemia in cancer patients
18. Cloning and expression of the human erythropoietin gene
19. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial
20. Clinical pharmacokinetics of epoetin (recombinant human erythropoietin)
21. Development and characterization of novel erythropoiesis stimulating protein (NESP)
22. Pathophysiology of the anemias
23. Erythropoiesis
24. Novel erythropoiesis stimulating protein (NESP) exhibits a prolonged serum half-life in oncology patients
25. The pharmacokinetics of darbepoetin alfa administered subcutaneously in patients with non-myeloid malignancies receiving multicycle chemotherapy
26. Predictability of pharmacokinetic properties of NESP administered once every 3 weeks in patients with normyeloid malignancies receiving cyclic chemotherapy
27. Novel erythropoiesis stimulating protein
28. Pharmaćokinetics of novel erythropoiesis stimulating protein compared with epoetin-α in dialysis patients
29. Changes in endogenous erythropoietin and the pharmacokinetics of darbepoetin alfa in patients with nonmyeloid malignancies receiving or not receiving chemotherapy
30. A Phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum-treatment for lung cancer
31. A Phase III, double-blind, placebo-controlled, randomized study of novel erythropoiesis stimulating protein (NESP) in patients undergoing platinum treatment for lung cancer
32. Darbepoetin alfa administered every 1 or 2 weeks (with no loss of dose efficiency) alleviates anemia in patients with solid tumors
33. Randomized, active-controlled, Phase I/II, dose-escalation study of NESP. administered weekly and every 2 weeks in patients with solid tumors
34. A randomized, blinded, placebo-controlled, Phase II, dose-finding study of NESP in patients with lymphoproliferative malignancies
35. Dose response of darbepoetin alfa is similar in anemic patients with solid tumors or lymphoproliferative malignancies
36. Randomized, active-controlled, Phase I/II, dose-comparison study of NESP administered weekly or every 2 weeks in patients with solid tumors
37. Randomized, double-blind, placebo-controlled, dose-finding study of darbepoetin alfa administered once every 3 (Q3W) or 4 (Q4W) weeks in patients with solid tumors
38. Recombinant human erythropoietin in the treatment of cancer and chemotherapy-induced anemia: Results of double-blind and open-label follow-up studies
39. Open-label, Phase I/II dose escalation study of NESP in patients with chronic anemia of cancer
40. Improvement in haemoglobin levels improves health-related quality of life (HRQOL) of anaemic cancer patients
41. Pharmacokinetics of novel erythropoiesis stimulating protein (NESP) in cancer patients: Preliminary report